Updating results

Breast cancer (advanced or metastatic) - lapatinib [ID20]

In development [GID-TAG387] Expected publication date: TBC

Technology appraisal guidance In development

Assessment, referral and management of Adrenal dysfunction

In development [GID-NG10052] Expected publication date: TBC

NICE guideline In development

Pulmonary arterial hypertension (adults) - drugs [ID12]

In development [GID-TAG382] Expected publication date: TBC

Technology appraisal guidance In development

Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]

In development [GID-TA10081] Expected publication date: TBC

Technology appraisal guidance In development

Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

In development [GID-TAG321] Expected publication date: TBC

Technology appraisal guidance In development

Leukaemia (acute lymphoblastic) - dasatinib [ID386]

In development [GID-TAG399] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]

In development [GID-TA10140] Expected publication date: TBC

Technology appraisal guidance In development

Macular oedema (diabetic) - pegaptanib sodium [ID452]

In development [GID-TAG280] Expected publication date: TBC

Technology appraisal guidance In development

Atherothrombotic events - vorapaxar [ID616]

In development [GID-TAG493] Expected publication date: TBC

Technology appraisal guidance In development

Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

In development [GID-TAG423] Expected publication date: TBC

Technology appraisal guidance In development

Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

In development [GID-TAG511] Expected publication date: TBC

Technology appraisal guidance In development

Diabetic foot ulcers - new treatments [ID381]

In development [GID-TAG371] Expected publication date: TBC

Technology appraisal guidance In development

T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

In development [GID-TAG433] Expected publication date: TBC

Technology appraisal guidance In development

Venous thromboembolism (prevention) - rivaroxaban [ID463]

In development [GID-TAG427] Expected publication date: TBC

Technology appraisal guidance In development

Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

In development [GID-IP2806] Expected publication date: TBC

Interventional procedures guidance In development

Lymphoma (mantle cell, relapsed, refractory) - lenalidomide [ID739]

In development [GID-TAG508] Expected publication date: TBC

Technology appraisal guidance In development

Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

In development [GID-TAG526] Expected publication date: TBC

Technology appraisal guidance In development

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

In development [GID-TAG393] Expected publication date: TBC

Technology appraisal guidance In development

Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

In development [GID-TAG278] Expected publication date: TBC

Technology appraisal guidance In development

Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention

In development [GID-IP1238] Expected publication date: TBC

Interventional procedures guidance In development

Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

In development [GID-TA10099] Expected publication date: TBC

Technology appraisal guidance In development

Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica

In development [GID-IP2803] Expected publication date: TBC

Interventional procedures guidance In development

Venous leg ulcers - new treatments [ID394]

In development [GID-TAG370] Expected publication date: TBC

Technology appraisal guidance In development

Head and neck cancer - intensity modulated radiotherapy [ID15]

In development [GID-TAG397] Expected publication date: TBC

Technology appraisal guidance In development

Glaucoma - lerdelimumab (CAT-152) [ID383]

In development [GID-TAG381] Expected publication date: TBC

Technology appraisal guidance In development

Personal, social, health and economic education focusing on sex and relationships and alcohol education

In development [GID-PHG0] Expected publication date: TBC

NICE guideline In development

Constipation (opioid induced) - lubiprostone [ID646]

In development [GID-TAG367] Expected publication date: 01 October 2014

Technology appraisal guidance In development

Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]

In development [GID-TAG372] Expected publication date: TBC

Technology appraisal guidance In development

Multiple sclerosis - sativex [ID387]

In development [GID-TAG368] Expected publication date: TBC

Technology appraisal guidance In development

Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

In development [GID-TAG384] Expected publication date: TBC

Technology appraisal guidance In development

Ex utero intrapartum therapy for fetal obstruction

In development [GID-IP1156] Expected publication date: TBC

Interventional procedures guidance In development

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

In development [GID-TAG388] Expected publication date: TBC

Technology appraisal guidance In development

Psoriasis - briakinumab (suspended) [ID65]

In development [GID-TAG412] Expected publication date: TBC

Technology appraisal guidance In development

Osteoarthritis - diacerein [ID332]

In development [GID-TAG250] Expected publication date: TBC

Technology appraisal guidance In development

Melanoma (advanced and metastatic) - temozolomide [ID316]

In development [GID-TAG401] Expected publication date: TBC

Technology appraisal guidance In development

Kidney transplantation (rejection) - everolimus [ID117]

In development [GID-TAG241] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]

In development [GID-TAG416] Expected publication date: TBC

Technology appraisal guidance In development

Peroral endoscopic myotomy (POEM) for achalasia

In development [GID-IP1229] Expected publication date: TBC

Interventional procedures guidance In development

Extra corporeal membrane oxygenation for acute heart failure in children

In development [GID-IP1153] Expected publication date: TBC

Interventional procedures guidance In development

Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]

In development [GID-TA10087] Expected publication date: 27 December 2017

Technology appraisal guidance In development

Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children

In development [GID-IP1170] Expected publication date: TBC

Interventional procedures guidance In development

Cutting blocks for total knee arthroplasty

In development [GID-IP1112] Expected publication date: TBC

Interventional procedures guidance In development

Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

In development [GID-IP1151] Expected publication date: TBC

Interventional procedures guidance In development

Leukaemia (chronic myeloid) - nilotinib (discontinued) [ID79]

In development [GID-TAG408] Expected publication date: 01 May 2011

Technology appraisal guidance In development

Intravaginal sling for stress urinary incontinence

In development [GID-IP267] Expected publication date: TBC

Interventional procedures guidance In development

Degradable surgical implant

In development [GID-IP1197] Expected publication date: TBC

Interventional procedures guidance In development

Nintedanib for previously treated metastatic colorectal cancer [ID1030]

In development [GID-TA10138] Expected publication date: TBC

Technology appraisal guidance In development

Pancreatic cancer - capecitabine [ID389]

In development [GID-TAG394] Expected publication date: TBC

Technology appraisal guidance In development

MRI guided focussed ultrasound for chronic pain

In development [GID-IP1043] Expected publication date: TBC

Interventional procedures guidance In development

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis [ID1521]

In development [GID-TA10471] Expected publication date: 04 March 2020

Technology appraisal guidance In development